Omics-Based Clinical Trials Market Size is valued at USD 29.51 billion in 2023 and is predicted to reach USD 54.42 billion by the year 2031 at a 8.13% CAGR during the forecast period for 2023-2031.
Omics-based clinical trials represent a significant shift towards more precise and personalized healthcare, offering the promise of better-targeted therapies with higher efficacy and fewer side effects. As the field evolves, continued advancements in omics technologies, bioinformatics, and regulatory policies will further enable the integration of these approaches into clinical research and practice. The omics-based clinical trials market focuses on clinical studies that employ omics technologies. Omics is the comprehensive study of various biological components such as genomics, transcriptomics, proteomics, metabolomics, and epigenomics, which allows researchers to analyze and understand an organism's molecular profiles and interactions, resulting in advances in personalized medicine and targeted therapies.
Pharmaceutical and biotechnology companies, academic research institutions, contract research organizations (CROs), and government agencies are among the stakeholders in the omics-based clinical trials market. They work together to design and conduct clinical trials that incorporate omics technologies, with the goal of accelerating the development of targeted therapies and better patient outcomes. With continued breakthroughs and increased use, omics-based trials are predicted to have a significant impact on the future of precision medicine and personalized healthcare.
Several market drivers contribute to the growth of the omics-based clinical trials market, including technological advancements, precision medicine, the rising burden of chronic diseases, regulatory support, collaborations and partnerships, cost reduction and accessibility, and increasing data availability and analysis capabilities. Technology has enhanced the efficiency, accuracy, and cost-effectiveness of biological data analysis, whereas precision medicine seeks to give tailored therapies based on an individual's genetic and molecular traits. Regulatory agencies acknowledge the importance of omics technologies in drug development and patient care, and stakeholder alliances and partnerships promote knowledge exchange, speed research, and drive market expansion. Cost reduction and accessibility have enabled greater implementation of omics-based techniques, resulting in market growth. Data availability and processing skills have enabled researchers to extract useful insights from complicated biological data, resulting in increased demand for omics-based clinical trials.
The Omics-Based Clinical Trials Market is segmented by phase type, study design type and indication type. Based on phase type, the market is divided into Phase I, Phase III, Phase II and lastly, Phase IV. By study design type, the market is segmented into interventional studies, observational studies, and expanded access studies. By indication type, the market is segmented into oncology, respiratory diseases, cardiology, skin diseases, CNS diseases, immunology, genetic diseases, and others.
The phase II category controlled the market for omics-based clinical studies. This is due to the enormous number of current clinical trials in phase II. In 2023, phase II clinical trials had the most projects, and this trend is projected to continue as company and non-industry sponsors increase their R&D investments. Furthermore, the segment's expansion is predicted to be driven by the globalization of clinical trials, the increasing number of industry-sponsored and non-industry-sponsored clinical studies in phase II, and the complexity of phase II clinical trials.
The expanded access studies segment is expected to grow at a lucrative CAGR of 8.6% during the forecast period. Interventional study designs have been shown to produce the most trustworthy results in epidemiology research in genomics and other omics-based investigations. Intervention studies are often classified as either preventative or therapeutic. When an interventional study design is significantly randomized, the statistical test of significance is easily interpretable for researchers, making the study extremely useful in omics-based research.
North America led the market for omics-based clinical trials. This might be ascribed to significant R&D investments, the existence of multinational players, and efforts to develop fresh patents. Furthermore, Asia Pacific is the rapidly expanding market, as many developed countries invest in Asia-Pacific regions. Furthermore, recruitment for clinical trials is increasing in Asia compared to North America and Europe. This is owing to the vast patient population and low trial costs. The region has a well-developed clinical research industry, with numerous international pharmaceutical companies and CROs operating there for over two decades. Many organizations are expanding production facilities in the region to conduct omics-based research.
|
Report Attribute |
Specifications |
|
Market Size Value in 2023 |
USD 29.51 Bn |
|
Market Size Value in 2031 |
USD 54.42 Bn |
|
Growth Rate CAGR |
CAGR of 8.13% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Phase Type, Study Design Type and Indication Type |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Parexel International Corporation, Pharmaceutical Product Development (PPD), Charles River Laboratory, ICON plc, SGS SA, Eli Lilly and Company, Pfizer Inc., Covance Inc., Novo Nordisk, and Rebus Bio |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Omics-Based Clinical Trials Market Snapshot
Chapter 4. Global Omics-Based Clinical Trials Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Phase Type Estimates & Trend Analysis
5.1. by Phase Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Phase Type:
5.2.1. Phase I
5.2.2. Phase II
5.2.3. Phase III
5.2.4. Phase IV
Chapter 6. Market Segmentation 2: by Study Design Type Estimates & Trend Analysis
6.1. by Study Design Type & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Study Design Type:
6.2.1. interventional studies
6.2.2. observational studies
6.2.3. expanded access studies
Chapter 7. Market Segmentation 3: by Indication Type Estimates & Trend Analysis
7.1. by Indication Type & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Indication Type:
7.2.1. oncology
7.2.2. cardiology
7.2.3. respiratory diseases
7.2.4. skin diseases
7.2.5. CNS diseases
7.2.6. immunology
7.2.7. genetic diseases
7.2.8. others
Chapter 8. Omics-Based Clinical Trials Market Segmentation 6: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Omics-Based Clinical Trial Market Revenue (US$ Million) Estimates and Forecasts by Phase Type, 2019-2031
8.1.2. North America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Study Design Type, 2019-2031
8.1.3. North America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Indication Type, 2019-2031
North America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.2. Europe
8.2.1. Europe Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Phase Type, 2019-2031
8.2.2. Europe Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Study Design Type, 2019-2031
8.2.3. Europe Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Indication Type, 2019-2031
8.2.4. Europe Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.3. Asia Pacific
8.3.1. Asia Pacific Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Phase Type, 2019-2031
8.3.2. Asia Pacific Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Study Design Type, 2019-2031
8.3.3. Asia-Pacific Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Indication Type, 2019-2031
8.3.4. Asia Pacific Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.4. Latin America
8.4.1. Latin America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Phase Type, 2019-2031
8.4.2. Latin America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Study Design Type, 2019-2031
8.4.3. Latin America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Indication Type, 2019-2031
8.4.4. Latin America Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Phase Type, 2019-2031
8.5.2. Middle East & Africa Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Study Design Type, 2019-2031
8.5.3. Middle East & Africa Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by Indication Type, 2019-2031
8.5.4. Middle East & Africa Omics-Based Clinical Trials Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Pfizer Inc.
9.2.2. Covance Inc.
9.2.3. Parexel International Corporation
9.2.4. Charles River Laboratory
9.2.5. Icon Plc
9.2.6. Eli Lilly and Company
9.2.7. Rebus Bio
9.2.8. Novo Nordisk
Omics-Based Clinical Trials Market By Phase Type -
Omics-Based Clinical Trials Market By Study Design Type -
Omics-Based Clinical Trials Market By Indication Type -
Omics-Based Clinical Trials Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
